Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known						
Application Number	NOT YET ASSIGNED	_				
Filing Date	ON EVEN DATE HEREWITH					
First Named Inventor	Ramon TORRES	_				
Group Art Unit						
Examiner Name						
Attorney Docket Number	TORRES=1B					

Number No.1 Number No.1 Number Kind Code* (fi known) Kind Code*		U.S. PATENT DOCUMENTS						
Number No. Number Kind Code (fi known)		wines Cite Kind Code			Name of Patentee or Applicant		Pages, Columns, Lines,	
AR RE 33,653 MARK et al. 07-30-1891 AB 4,588,585 MARK et al. 05-13-1988 AC 4,737,462 MARK et al. 04-12-1988 AD 4,904,584 SHAW 02-27-1990 AE 4,989,314 MARK et al. 09-25-1990 AE 4,989,314 MARK et al. 09-25-1990 AF 4,985,195 NAMEN et al. 10-23-1990 AG 5,017,891 LE et al. 05-21-1991 AH 5,116,943 KOTHS et al. 05-21-1991 AJ 5,137,872 SEELY et al. 08-11-1992 AJ 5,534,617 CUNNINGHAM et al. 07-09-1998 AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-31-1997 AN 5,633,352 DALBGGE et al. 05-27-1997 AN 5,633,352 DALBGGE et al. 06-03-1997 AN 5,635,604 DALBGGE et al. 06-03-1997 AD 5,686,666 BASS et al. 11-18-1997 AP 5,688,666 BASS et al. 11-18-1997 AR 5,712,380 KENDALL et al. 12-09-1997 AR 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,722,561 HOUGHTON et al. 02-24-1998 AY 5,726,307 SCHOEN et al. 03-30-1998 AV 5,726,307 SCHOEN et al. 03-30-1998 AV 5,726,319 LIN et al. 03-30-1998 AX 5,731,317 LU et al. 03-30-1998 BA 5,767,124 DRANGUE et al. 06-1998 BA 5,767,124 DRANGUE et al. 06-1998 BB 5,773,441 HIPSKIND et al. 06-1998 BB 5,773,441 HIPSKIND et al. 06-1998 BB 5,773,441 HIPSKIND et al. 06-1998 BB 5,779,693 CHARRUM et al. 07-07-1998 BB 5,789,597 DEGHENGHI et al. 08-1998 BB 5,789,597 DEGHENGHI et al. 08-1998 BB 5,804,678 CHARRUM ET al. 08-1998 BB 5,807,805 DEGHENGHI et al. 09-08-1998		Cite No.1	Mumber				Relevant Figures Appear	
AB					MARK et al.	07-30-1991		
AD 4,904,584 SHAW 02-27-1890 AE 4,959,314 MARK et al. 09-25-1990 AF 4,955,195 NAMEN et al. 10-23-1890 AG 5,017,691 LEE et al. 05-21-1891 AH 5,118,943 KOTHS et al. 05-21-1891 AJ 5,137,872 SEELY et al. 08-11-1892 AJ 5,534,617 CUNNINGHAM et al. 07-09-1996 AK 5,597,709 ROSEN et al. 01-28-1897 AL 5,612,470 THORNER et al. 05-18-1897 AM 5,633,352 DALBØGE et al. 05-27-1897 AN 5,633,352 DALBØGE et al. 06-33-1897 AO 5,654,010 JOHNSON et al. 08-05-1897 AP 5,688,666 BASS et al. 11-18-1897 AR 5,712,330 KENDALL et al. 12-09-1897 AR 5,712,330 KENDALL et al. 01-27-1998 AR 5,721,251 CHEN et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AN 5,728,319 LIN et al. 03-10-1998 AN 5,728,319 LIN et al. 03-10-1998 AN 5,728,319 LIN et al. 03-10-1998 AN 5,733,137 LU et al. 03-24-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,773,441 HIPSKIND et al. 06-31-1998 BB 5,779,477 SCHALLY et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-18-1998 BB 5,793,771 DEGMENGHI et al. 08-18-1998 BB 5,799,577 DEGMENGHI et al. 08-18-1998 BB 5,807,7955 DEGMENGHI et al. 09-03-1998		AB	4,588,585		MARK et al.	05-13-1986		
AD 4,905,314 MARK et al. 09-25-1990 AE 4,959,314 MARK et al. 09-25-1990 AF 4,955,195 NAMEN et al. 10-23-1990 AG 5,017,691 LEE et al. 05-21-1991 AH 5,116,943 KOTHS et al. 05-28-1992 AJ 5,137,672 SEELY et al. 06-11-1992 AJ 5,534,617 CUNNINGHAM et al. 07-09-1998 AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-28-1997 AN 5,633,352 DALBØGE et al. 05-27-1997 AN 5,633,352 DALBØGE et al. 06-03-1997 AN 5,635,604 DALBØGE et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,330 KENDALL et al. 12-09-1997 AS 5,721,250 MORRIELLO et al. 02-24-1998 AX 5,722,251 CHEN et al. 02-24-1998 AV 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,767,085 JOHANSEN et al. 06-16-1999 AX 5,767,124 DRASEN et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BC 5,776,901 BOWERS et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BB 5,773,447 SCHALLY et al. 07-07-1998 BB 5,779,112 NARGUND et al. 07-07-1998 BB 5,779,595 DEGHENGHI et al. 08-18-1998 BB 5,799,397 DEGHENGHI et al. 08-18-1998 BB 5,799,397 DEGHENGHI et al. 08-18-1998 BB 5,799,395 DEGHENGHI et al. 09-03-1998		AC	4,737,462		MARK et al.	04-12-1988		
AF 4,965,195 NAMEN et al. 10-23-1990 AG 5,017,691 LEE et al. 05-21-1991 AH 5,118,943 KOTHS et al. 05-28-1992 AJ 5,137,872 SEELY et al. 08-11-1992 AJ 5,534,617 CUNNINGHAM et al. 07-09-1998 AK 5,597,709 ROSEN et al. 05-18-1997 AL 5,612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 05-27-1997 AO 5,655,010 JOHNSON et al. 08-05-1997 AP 5,688,668 BASS et al. 11-18-1997 AR 5,712,380 KENDALL et al. 11-09-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-03-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,767,118 NARGUND et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 07-07-1998 BG 5,798,337 SOMES et al. 08-18-1998 BG 5,798,337 SCHOEN et al. 07-07-1998 BG 5,798,337 SCHOEN et al. 08-18-1998		AD	4,904,584		SHAW	02-27-1990		
AG 5,017,691		AE	4,959,314		MARK et al.	09-25-1990		
AH 5,118,943 KOTHS et al. 05-28-1992 AI 5,137,872 SEELY et al. 08-11-1992 AJ 5,534,817 CUNNINGHAM et al. 07-09-1998 AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,668 BASS et al. 11-18-1997 AR 5,712,330 KENDALL et al. 12-09-1997 AR 5,712,330 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AV 5,728,316 HOUGHTON et al. 03-03-1998 AV 5,728,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,731,317 LU et al. 03-10-1998 BA 5,767,124 DRANSEN et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,773,441 HIPSKIND et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BB 5,804,578 CHARKAVARTY et al. 09-15-1998 BB 5,807,985 DEGHENGHI et al. 09-15-1998		AF	4,965,195		NAMEN et al.	10-23-1990		
AI 5,137,872 SEELY et al. 08-11-1992 AJ 5,534,617 CUNNINGHAM et al. 07-09-1996 AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AR 5,712,350 KENDALL et al. 12-09-1997 AR 5,712,350 MORRIELLO et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AJ 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,767,124 DRAPER et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BC 5,776,901 BOWERS et al. 08-18-1998 BG 5,798,337 SCHOEN et al. 07-07-1998 BF 5,795,957 DEGHENGH et al. 07-07-1998 BF 5,795,957 DEGHENGH et al. 07-07-1998 BG 5,798,337 SCHOEN et al. 07-07-1998 BG 5,798,337 SCHOLN et al. 08-18-1998 BG 5,804,578 CHARRAVARTY et al. 08-18-1998 BG 5,804,578 CHARRAVARTY et al. 09-03-1998		AG	5,017,691		LEE et al.	05-21-1991		
AJ 5,534,817 CUNNINGHAM et al. 07-09-1996 AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 06-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,261 CHEN et al. 02-24-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,767,085 JOHANSEN et al. 06-18-1998 BA 5,767,124 DRAPER et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 07-07-1998 BB 5,775,112 NARGUND et al. 06-18-1998 BB 5,777,112 NARGUND et al. 07-07-1998 BB 5,779,112 NARGUND et al. 07-07-1998 BB 5,779,747 SCHALLY et al. 08-11-1998 BB 5,779,337 SOMERS et al. 07-07-1998 BB 5,798,337 SOMERS et al. 08-11-1998 BB 5,799,955 DEGHENGHI et al. 08-12-1998 BB 5,804,578 CHAKRAVARTY et al. 08-11-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,807,985 DEGHENGHI et al. 09-08-1998		AH	5,116,943		KOTHS et al.	05-26-1992		
AK 5,597,709 ROSEN et al. 01-28-1997 AL 5,612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,767,085 JOHANSEN et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BF 5,792,747 SCHALLY et al. 08-18-1998 BG 5,798,337 SCHERN et al. 08-18-1998 BG 5,807,985 DEGHENGHI et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BG 5,909,985 DEGHENGHI et al. 09-15-1998		Al	5,137,872		SEELY et al.	08-11-1992		
AL 5.612,470 THORNER et al. 05-18-1997 AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,767,085 JOHANSEN et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-18-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BF 5,792,977 SCHAELU et al. 07-07-1998 BF 5,792,747 SCHALLY et al. 07-07-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SCHAELY et al. 08-18-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BG 5,909,985 DEGHENGHI et al. 09-15-1998		Ą	5,534,617		CUNNINGHAM et al.	07-09-1996		
AM 5,633,352 DALBØGE et al. 05-27-1997 AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,668 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 03-03-1998 AU 5,726,307 SCHOEN et al. 03-10-1998 AV 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,767,085 JOHANSEN et al. 06-18-1998 AZ 5,767,118 NARGUND et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BB 5,773,441 HIPSKIND et al. 07-07-1998 BB 5,773,112 NARGUND et al. 07-07-1998 BB 5,773,112 NARGUND et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BB 5,773,441 NARGUND et al. 07-07-1998 BB 5,775,991 BOWERS et al. 07-07-1998 BB 5,775,991 BOWERS et al. 07-07-1998 BB 5,779,7112 NARGUND et al. 08-11-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BB 5,792,747 SCHALLY et al. 08-18-1998 BB 5,798,337 SOMERS et al. 09-25-1998 BB 5,807,985 DEGHENGHI et al. 09-08-1998 BB 5,807,985 DEGHENGHI et al. 09-08-1998		AK	5,597,709		ROSEN et al.	01-28-1997		
AN 5,635,604 DALBØGE et al. 06-03-1997 AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 03-03-1998 AU 5,726,307 SCHOEN et al. 03-10-1998 AV 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BB 5,777,112 NARGUND et al. 07-07-1998 BB 5,777,112 NARGUND et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BB 5,804,578 CHAKRAVARTY et al. 08-25-1998 BB 5,807,985 DEGHENGHI et al. 09-08-1998		AL	5,612,470		THORNER et al.	05-18-1997		
AO 5,654,010 JOHNSON et al. 08-05-1997 AP 5,688,666 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,722,251 CHEN et al. 03-03-1998 AU 5,723,616 HOUGHTON et al. 03-10-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,731,317 LU et al. 03-24-1998 AX 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BG 5,798,337 SOMERS et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,807,985 DEGHENGHI et al. 09-08-1998		AM	5,633,352		DALBØGE et al.	05-27-1997		
AP 5,688,668 BASS et al. 11-18-1997 AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 03-03-1998 AU 5,723,616 HOUGHTON et al. 03-10-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-18-1998 AZ 5,767,118 NARGUND et al. 06-18-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 08-11-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,807,985 DEGHENGHI et al. 09-15-1998		AN	5,635,604		DALBØGE et al.	06-03-1997		
AQ 5,696,089 FELIX et al. 12-09-1997 AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AU 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-18-1998 AZ 5,767,118 NARGUND et al. 06-18-1998 BA 5,767,124 DRAPER et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BB 5,777,112 NARGUND et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-25-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,807,985 DEGHENGHI et al. 09-15-1998		AO	5,654,010		JOHNSON et al.	08-05-1997		
AR 5,712,380 KENDALL et al. 01-27-1998 AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AU 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BB 5,777,112 NARGUND et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BG 5,798,337 SOMERS et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998 BB 5,804,578 CHAKRAVARTY et al. 09-08-1998		ΑĐ	5,688,666		BASS et al.	11-18-1997		
AS 5,721,250 MORRIELLO et al. 02-24-1998 AT 5,721,251 CHEN et al. 02-24-1998 AU 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AX 5,731,317 LU et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BB 5,792,747 SCHALLY et al. 08-11-1998 BG 5,798,337 SOMERS et al. 08-18-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-08-1998		AQ	5,696,089		FELIX et al.	12-09-1997		
AT 5,721,251 CHEN et al. 02-24-1998 AU 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-08-1998		AR	5,712,380		KENDALL et al.	01-27-1998		
AU 5,723,616 HOUGHTON et al. 03-03-1998 AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-08-1998		AS	5,721,250		MORRIELLO et al.	02-24-1998		
AV 5,726,307 SCHOEN et al. 03-10-1998 AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-08-1998		AT	5,721,251		CHEN et al.	02-24-1998		
AW 5,726,319 LIN et al. 03-10-1998 AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		ΑU	5,723,616		HOUGHTON et al.	03-03-1998		
AX 5,731,317 LU et al. 03-24-1998 AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 09-08-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		AV	5,726,307		SCHOEN et al.	03-10-1998		
AY 5,767,085 JOHANSEN et al. 06-16-1998 AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		AW	5,726,319		LIN et al.	03-10-1998		
AZ 5,767,118 NARGUND et al. 06-16-1998 BA 5,767,124 DRAPER et al. 06-16-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		AX	5,731,317		LU et al.	03-24-1998		
BA 5,767,124 DRAPER et al. 06-18-1998 BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		AY	5,767,085		JOHANSEN et al.	06-16-1998		
BB 5,773,441 HIPSKIND et al. 06-30-1998 BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		AZ	5,767,118		NARGUND et al.	06-16-1998		
BC 5,776,901 BOWERS et al. 07-07-1998 BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		BA	5,767,124		DRAPER et al.	06-16-1998		
BD 5,777,112 NARGUND et al. 07-07-1998 BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		BB	5,773,441		HIPSKIND et al.	06-30-1998		
BE 5,792,747 SCHALLY et al. 08-11-1998 BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		ВС	5,776,901		BOWERS et al.	07-07-1998		
BF 5,795,957 DEGHENGHI et al. 08-18-1998 BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		BD	5,777,112		NARGUND et al.	07-07-1998		
BG 5,798,337 SOMERS et al. 08-25-1998 BH 5,804,578 CHAKRAVARTY et al. 09-08-1998 BI 5,807,985 DEGHENGHI et al. 09-15-1998		BE	5,792,747		SCHALLY et al.	08-11-1998		
BH 5,804,578		BF	5,795,957		DEGHENGHI et al.	08-18-1998		
BI 5,807,985 DEGHENGHI et al. 09-15-1998		BG	5,798,337		SOMERS et al.	08-25-1998		
		вн	5,804,578		CHAKRAVARTY et al.	09-08-1998		
		ВІ	5,807,985		DEGHENGHI et al.	09-15-1998		
SP BJ 5,830,433 DEAN et al. 11-03-1998	SK	BJ	5,830,433		DEAN et al.	11-03-1998		

Examiner Signature	Stem 1 Fole	Date Considered	11/14/8
Signature	Mint 189	Considered	111.110

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Subatituta	for form 1449A/PTO			Complete if Known		
Substitute	IOI JOHN 1449AFTO			Application Numb r	NOT YET ASSIGNED	
INFO	RMATION D	ISC	LOSURE	Filing Date	ON EVEN DATE HEREWITH	
	EMENT BY			First Named Inventor	Ramon TORRES	
יאוט	LINE III		· LIOMIT	Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	2	of	8 .	Attorney Docket Number	TORRES=1B	

	U.S. PATENT DOCUMENTS							
		U.S. Patent		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,		
Examiner nitials*	Cite No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
4	BK	5,834,598		LOWMAN et al.	11-10-1998			
	BL	5,843,453		HOLDER et al.	12-01-1998			
$\neg \tau$	ВМ	5,846,936		FELIX et al.	12-08-1998			
$\neg \vdash$	BN	5,847,066		COY et al.	12-08-1998			
	во	5,849,700		SØRENSEN et al.	12-15-1998			
	ВР	5,849,704		SØRENSEN et al.	12-15-1998			
	BQ	5,849,535		CUNNINGHAM et al.	12-15-1998			
\neg	BR	5,851,992		SØRENSEN	12-22-1998			
	BS	5,597,797		CLARK	01-1997			
4	ВТ	5,137,872		SEELY et al.	08-1992			

	FOREIGN PATENT DOCUMENTS									
			Foreign Patent Nun	nber		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,		
Examiner Initials*		Office ³	Number	Kind (if knd	C006	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	™	
SP	ΒU	EPO	0075444B1			DE BOER et al.	03-30-1983			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²					
BU CARR et al., 5th Conference on Retroviruses and Opportunistic Infections "A syndrome of peripheral lipodystrophy (LD), hypertipidemia and insulin resistance due to HIV protease inhibitors (Pl's)", Chicago, IL, Page 410 (February 1-5, 1998)								
	BV MULLIGAN et al., 5 th Conference on Retroviruses and Opportunistic Infections "Evidence of unique metabolic leffects of protease inhibitors", Chicago, IL, Page 414 (February 1-5, 1998)							
	BW	KERULY et al., 5 th Conference on Retroviruses and Opportunistic Infections "Diabetes and hyperglycemia in patients receiving protease inhibitors", Chicago, IL, Page 415 (February 1-5, 1998)						
	BX DONG et al., 5 th Conference on Retroviruses and Opportunistic Infections "Diabetes and use of protease inhibitors", Chicago, IL, Page 416 (February 1-5, 1998)							
	BY	LO et al., "Buffalo hump" in men with HIV-1 infection, The Lancet, 351:867-870 (March 21, 1998)						
	BZ	MILLER et al., "Visceral abdominal-fat accumulation associated with use of indinavir", The Lancet, 351:871-875 (March 21, 1998)						
CA VIRABEN et al., "Indinavir-associated lipodystrophy", AIDS, 12:F37-F39 (1998)								

Examiner Signature	Stanow A pla	Date Considered	4/5

£

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Cubatitute 6	or form 1449A/PTO			Complete if Known		
Substitute i	0110HH 1449AP10			Application Number	NOT YET ASSIGNED	
INFO	RMATION D	SC	LOSURE	Filing Date	ON EVEN DATE HEREWITH	
	EMENT BY			First Named Inventor	Ramon TORRES	
3170		-40		Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	3	of	8	Attorney Docket Number	TORRES=1B	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
ge	СВ	ADELMAN et al., "In vitro deletional mutagenesis for bacterial production of the 20,000-Dalton form of human pituitary growth hormone", <u>DNA</u> , 2:183-193 (1983)	
\wedge		ALBERTSSON-WIKLAND et al., "Daily subcutaneous administration of human growth hormone in growth hormone deficient children", Acta Poediatr Scand, 75:89-97 (1986)	
		BECKER et al., "Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormone", <u>Biotechnology and Applied Biochemistry</u> , 9:478-487 (1987)	
		BEWLEY et al., "The chemistry of human pituitary growth hormone", Adv. Emzymol. Related Areas, 42:73-166 (1975)	
		DENOTO et al., "Human growth hormone DNA sequence and mRNA structure: possible alternative splicing", Nucleic Acids Research, 9:3718-3731 (1981)	
	CG	HENDRICKS et al., "Plasma clearance of intravenously administered pituitary human growth homone: gel filtration studies of heterogeneous components", <u>Journal of Clinical Endocrinology and Metabolism</u> , 60:864-867 (1985)	
	СН	JØRGENSEN et al., "Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man a double-blind cross-over study", <u>Acta Endocrinologica (Copenh)</u> , 116:381-386 (1987)	
	CI	JØRGENSEN et al., "Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats", Pharmacology & Toxicology, 63:129-134 (1988)	,
	ငၪ	LEWIS et al., "An interchain disulfide dimmer of human growth hormone", The Journal of Biological Chemistry, 252:3697-3702 (1977)	
		LEWIS et al., "Enhancement of the hyperglycemic activity of human growth hormone by enzymic modification", <u>Endo</u> , 101:1587-1603 (1977)	
	CL	LEWIS et al., "Human Growth hormone: additional members of the complex*", Endo, 104:1256-1265 (1979)	
	СМ	LEWIS et al., "Altered proteolytic cleavage of human growth hormone as a result of deamidation", The Journal Of Biological Chemistry, 256:11645-11650 (1981)	
SF	CN	HO et al., "Indinavir-associated facial lipodystrophy in HIV-infected patients", AIDS Patient Care and STDs, 13:11-16 (1999)	
0. 0 0 0 E 0.00 0.00			

		a management of the second		
Examiner Signature	Stamp bly	Date Considered	11/14/5	

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute (or form 1449A/PTO			Complete if Known		
				Application Number	NOT YET ASSIGNED	
INFO	RMATION D	SC	LOSURE	Filing Date	ON EVEN DATE HEREWITH	
STAT	EMENT BY	ΔP	PLICANT	First Named Inventor	Ramon TORRES	
		<i>, 40</i>		Group Art Unit		
	(use as many sheets	s as n	ecessary)	Examiner Name		
Sheet	4	of	8	Attorney Docket Number	TORRES=18	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner nitials*	No. 1 publisher, city and/or country where published		T²					
Se	СО	KOSMISKI et al., "An increase in abdominal girth on protease inhibitor therapy is associated with visceral obesity and metabolic disturbances that closely resemble syndrome", 1 st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 49-55 (1999)						
	СР	HENRY et al., "Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities", <u>The Lancet,</u> 352:1031-1035 (1998)						
\int	CQ	ENGELSON et al., "Altered body fat distribution in HIV infection:regional body composition measurements by whole body MRI and DXA scans", 12th World AIDS Conference Geneva, 471-471 (June 28-July 3 1998)						
	CR	HENRY et al., "Severe premature coronary artery disease with protease inhibitors", The Lancet, 351:1328 (1998)						
		CARR et al., "Pathogenesis of HIV-1-proteases inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance", The Lancet, 351:1881-1883 (1998)						
	СТ	CARR et al., "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", <u>AIDS</u> , F51-F58 (1998)						
	CV	BRINKMAN et al., "The first international workshop on adverse drug reactions and lipodystrophy in HIV session 4: related syndromes mitochondrial toxicity of nucleosides" The Body: An AIDS and HIV Information Resource, Abstract No. 9 (1999)	,					
	CW	ABSTRACT - TORRES et al., "The effect of recombinant human growth hormone on protease-inhibitor- associated fat maldistribution syndrome", 675						
	СХ	ABSTRACT – VIARD et al., "Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor", Abstract No. 026						
	CY	WANKE et al., "Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV", AIDS, 2099-2103 (1999)						
	CZ	ABSTRACT 031 – RUIZ et al., "A multicentre, randomized, open-label, comparative trial of the clinical, immunological and virological benefit of switching thePI by nevirapine in HAART-experienced patients suffering lipodystrophy", 35						
	DA	ABSTRACT 068 – ROZENBAUM et al., "Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome"						
SP	DB	ABSTRACT 054 – MOLYLE et al., "Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz"						

Examiner Signature	Slam H. Ha	Date Considered	11/14/5	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute 6	or form 1449A/PTO			Complete if Known		
				Application Number	NOT YET ASSIGNED	
INFO	RMATION D)ISC	CLOSURE	Filing Date	ON EVEN DATE HEREWITH	
	EMENT BY			First Named Inventor	Ramon TORRES	
		20		Group Art Unit		
	(use as many shee	ts as n	ecessary)	Examiner Name		
Sheet	5	of	8	Attorney Docket Number	TORRES=1B	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published								
SP	DC	MILLER et al., "Visceral abdominal-fat accumulation associated with use of Indinavir", The Lancet, 351:871-875 (1998)						
1	DD	ABSTRACT 042 - MILANO et al., "Two case reports of unusual lipomatous growths associated with combination antiretroviral therapy"						
	DE	ABSTRACT 038 - MAGGI et al., "Precvocious lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors"						
	DF ABSTRACT 018 – MERCIE et al., "Case report of lipidystrophy observations in patients naïve of protease inhibitor treatment, anguitaine cohort"							
	DG	KRENTZ et al., "Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex", <u>Journal of Acquired Immune Deficiency Syndromes</u> , 6(3)245-251 (1993)						
DH ENGELSON et al., "Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imagining 1-3, Am J Clin Nutr, 69:1162-1169 (1999)								
	DI	BECKER et al., "A nondiabetogenic derivative of human growth hormone", 342:108						
	DJ	BJORNTORP et al., "Review the regulation of adipose tissue distribution in humans", <u>International Journal of Obesity</u> , 20:291-302 (1996)						
	DK	CARR et al., "Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study", The Lancet, 353:2093-2099 (1999)						
		CHEN et al., "The human growth hormone locus: nucleotide sequence, biology, and evolution", <u>Genomics,</u> 4:479-497 (1989)						
DM ABSTRACT 006 - ENGELSON et al., "Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection: interim analysis", <u>Antiviral Therapy</u> , 4(Supplement 2):19 (1999)								
	DN	SIUNG et al., "Use of bacterioncin release protein in <i>E. Coli</i> for excretion of human growth hormone into the ulture medium", Bio/technology 7:267-271 (1989)						
SP	DO	JONES et al., "Crystallization of authentic recombinant human growth hormone", <u>Bio/technology</u> , 5:499-500 (1987)						
			_					

Examiner Signature	Slum Hole	Date Considered	11/14/8

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Subatituta fi	or form 1449A/PTO			Complete If Known			
Substitute in	31 101111 14482110			Application Number	NOT YET ASSIGNED		
INFO	RMATION DI	SC	LOSURE	Filing Date	ON EVEN DATE HEREWITH		
TATS	EMENT BY	AP	PLICANT	First Named Inventor	Ramon TORRES		
		~ 4 0		Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name -			
Sheet	6	of	8	Attorney Docket Number	TORRES=1B		

Cite	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the				
No.'	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),				
DP LEWIS et al., "A naturally occurring structural variant of human growth hormone", The Journal of Biolo Chemistry, 253:2679-2687 (1978)					
	Biological Chemistry, 11645-11650 (1981)				
	205:602-607 (1979)				
	ABSTRACT P145 - MAUSS et al., "Successful treatment of PI-Induced visceral abdominal-fat accumulation with R-human growth hormon"				
DT	MOCROFT et al., *Changes in AIDS-defining illnesses in a London clinic, 1987-1998", <u>Journal of Acquired</u> Immune Deficiency Syndromes and Human Retrovlrology, 21:401412 (1999)				
DU	MOORE et al., "Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine", Endocrinology, 122:2920-2926 (1988)				
	WINDISCH et al., "Recombinant human growth hormone for AIDS-associated wasting", The Annals of Pharmacotherapy, 32:437-445 (1998)				
DW	KOTLER et al., "Studies of body composition and fat distribution in HIV-infected and control subjects", <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> , 20:228-237 (1999)				
	PINEDA, "Predictable upwelling and the shoreward transport of planktonic larvae by internal Tidal Bores", Science, 548				
DY	CARR et al., "Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance" The Lancet, 351:1881-1883 (1998)				
DZ	CARR et al., "Fast track a syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", AIDS, 12:F51-F58 (1998)				
EA	MICHAELS et al., "Differences in the incidence rates of opportunistic processes before and after the availability of protease inhibitors", 5th Conference on Retroviruses and Opportunistic Infections, (February 1-5, 1998)				
EВ	DONG et al., "Diabetes and use of protease inhibitors", 12th World AIDS Conference Geneva, (June 28 – July 3 1998)				
	DQ DR DS DT DU DV DW DX DZ	DQ LEWIS et al., "Altered proteolytic deavage of human growth hormone as a result of deamidation", The Journal of Biological Chemistry, 11645-11650 (1981) DR ZUREK et al., "Human growth hormone: complementary DNA cloning and expression in bacteria", Science 205:602-607 (1979) DS ABSTRACT P145 - MAUSS et al., "Successful treatment of PI-Induced visceral abdominal-fat accumulation with R-human growth hormon" DT MOCROFT et al., "Changes in AIDS-defining illnesses in a London clinic, 1987-1998", Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 21:401412 (1999) DU MOORE et al., "Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine", Endocrinology, 122:2920-2926 (1988) DV WINDISCH et al., "Recombinant human growth hormone for AIDS-associated wasting", The Annals of Pharmacotherapy, 32:437-445 (1998) WKOTLER et al., "Studies of body composition and fat distribution in HIV-infected and control subjects", Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20:228-237 (1999) DX PINEDA, "Predictable upwelling and the shoreward transport of planktonic larvae by internal Tidal Bores", Science, 548 DY CARR et al., "Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance" The Lancet, 351:1881-1883 (1998) DZ CARR et al., "Fast track a syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", AIDS, 12:F51-F58 (1998) EA MICHAELS et al., "Differences in the incidence rates of opportunistic processes before and after the availability of protease Inhibitors", 5th Conference on Retroviruses and Opportunistic Infections, (February 1-5, 1998)			

1	Examiner Signature	Sham	11/16	Date Considered	14/15	
•						

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute fo	or form 1449A/PTO			Complete if Known		
0000000	27 10.117 7 7 7 0.7 1 1 0			Application Number	NOT YET ASSIGNED	
INFO	RMATION DI	SC	LOSURE	Filing Date	ON EVEN DATE HEREWITH	
STAT	EMENT BY		PLICANT	First Named Inventor	Ramon TORRES	
		-		Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	7	of	8	Attorney Docket Number	TORRES=1B	

	-	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
SP	EC	ABSTRACT No. PB0895 - MUURAHAINEN et al., Detection of occult wasting by BIA technology", International Conference AIDS, 10(2)220 (Aug. 7-12 1994)	
1	ED	VIRABEN et al., "Fast Track indinavir-associated lipodystrophy", AIDS, 12::F37-F39 (1998)	
	EE	LEWIS et al., "The 20,000-Dalton variant of human growth hormone' location of the amino acid deletions", Biochemical and Biophysical Research Communications, 92:511-516 (1980)	
	EF	BJORNTORP et al., "Abdominal obesity and the development of noninsulin-dependent diabetes mellitus", <u>Diabetes/Metabolism Reviews</u> , 4:615-622 (1998)	
	EG	JONES et al., "Crystallization of authentic recombinant human growth hormone", <u>Biotechnology</u> , 5:499-500 (1987)	
	EH	MARTIAL et al., "Human growth hormone: complementary DNA cloning and expression in bacteria", <u>Science</u> , 602-607 (1979)	
	EI	BEWLEY et al., "Sequence comparision of human pituitary growth hormone, human chorionic somatomammotropin, and ovine pituitary growth and lactogenic hormones", Int. J. Peptide Protein Res., 4:281-287 (1972)	
	EJ	ABSTRACT 010 - CHENG, "Lipodystrophy in HIV: a community perspective" (1999)	
	EK	CUNNINGHAM et al., "Dimerization of human growth hormone by Zinc", Science, 253:544-548 (1991)	
	EL	ABSTRACT 006 - ENGELSON et al., "Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection: interim analysis" (1999)	
	EM	ABSTRACT 336*/32173 - KOTLER et al., "Alterations in body fat distribution in HIV-infected men and women" 12 World AIDS Conference Geneva (June 28-July 3 1998)	
	EN	ABSTRACT 022 - MUURAHAINEN et al., "The SALSA (self-ascertained lipodystrophy syndrome assessment) cohort: abnormalities in cases compared to controls" (1999)	
	EO	ABSTRACT 063 – MUURAHAINEN et al., "Abnormalities in HIV-associated lipodystrophy syndrome that vary by weight status" (1999)	
SP	EP	ABSTRACT 177*/12373 - DONG et al., "Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy" (1998)	

		NAME OF THE PARTY OF THE PARTY AND THE PARTY OF THE PARTY.			
Examiner Signature	Stem	A Hay	Date Considered	1/19	1/5
				The state of the s	

. .

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449A/PTO			· Complete if Known		
300301016	107 101111 1443747 10			Application Number	NOT YET ASSIGNED	
INFO	RMATION D	ISC	LOSURE	Filing Date	ON EVEN DATE HEREWITH	
STAT	EMENT BY	ΔΡ	PLICANT	First Named Inventor	Ramon TORRES	
UIA			. 2.0/	Group Art Unit		
	(use as many sheets	s as n	ecessary)	Examiner Name		
Sheet	8	of	8	Attorney Docket Number	TORRES=1B	

Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the	
Examiner Cite Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numb publisher, city and/or country where published	
SF EQ Mayo, Mol. Endocrinology, 6:1734-1744 (1992)	
ER DENOTO et al., <u>Nucleic Acids Research</u> , 9(15)3719-3730 (1991)	
ES KRENTZ et al., Anthropometic, metabolic, and immunological effects of recombinant growth horm and AIDS-related complex, <u>J. Acquir Immune Defic Syndr.</u> , 6(3)245-251 (1993)	none in AIDS
ET WINDISCH et al., Recombinant human growth hormone for AIDS-associated wasting, Ann Pharm 32(4):437-45 (1998)	nacother,
EU JAMES et al., Successful treatment of "buffalo hump" with growth hormone" AIDS treatment news (1998)	;, 298:5-6
EV MAUS et al., Successful treatment of PI-induced visceral abdominal fat accumulation with R-huma hormone, AIDS, 12 Sup 4:145 (1998)	an growth
Examiner Signature Signature Date Considered 1/14/8	5-

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.